Comparative Pharmacology
Head-to-head clinical analysis: AIRDUO DIGIHALER versus ALVESCO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AIRDUO DIGIHALER versus ALVESCO.
AIRDUO DIGIHALER vs ALVESCO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Salmeterol is a long-acting beta2-adrenergic agonist (LABA) that relaxes bronchial smooth muscle by increasing cyclic AMP. Fluticasone propionate is a corticosteroid with anti-inflammatory activity that inhibits inflammatory mediators and cells.
Ciclesonide is a prodrug that is converted to the active metabolite des-ciclesonide, which has anti-inflammatory activity by binding to glucocorticoid receptors, thereby inhibiting inflammatory mediators such as cytokines and leukotrienes.
Two inhalations (umeclidinium 62.5 mcg and vilanterol 25 mcg per inhalation) orally once daily.
Inhalation: 160 mcg twice daily (morning and evening). May be increased to 320 mcg twice daily if inadequate response. Maximum 640 mcg twice daily.
None Documented
None Documented
Fluticasone furoate: terminal elimination half-life is approximately 24 hours. Vilanterol: terminal elimination half-life is approximately 11 hours. The long half-life of fluticasone furoate supports once-daily dosing, while vilanterol's half-life allows for sustained bronchodilation over 24 hours.
Terminal elimination half-life is approximately 2-3 hours for the systemically absorbed fraction; however, the receptor occupancy half-life is significantly longer due to lipophilic tissue binding, providing therapeutic duration of 12 hours.
Fluticasone furoate and vilanterol are primarily eliminated via biliary/fecal routes. For fluticasone furoate, approximately 90% of an oral dose is excreted in feces as parent drug and metabolites, with <1% in urine. Vilanterol is predominantly excreted via feces (∼70%) as metabolites, with ∼20% in urine.
Primarily hepatic metabolism (CYP3A4) to less active metabolites; renal excretion accounts for <10% unchanged; fecal excretion as metabolites ~80%.
Category C
Category C
Inhaled Corticosteroid/LABA Combination
Inhaled Corticosteroid